In context
In August 2024, the intersection of robotics and biopharmaceutical manufacturing was gaining momentum as companies sought to address the challenges of scaling cell therapy production. Yaskawa Electric, a leading industrial robot manufacturer, and Astellas Pharma, a global pharmaceutical company, announced a memorandum of understanding (MOU) to explore building an innovative cell therapy platform that integrates robotics and pharmaceutical technologies.
What was reported
The MOU is a non-binding agreement initiating discussions between the two companies. They aim to jointly develop a platform that could seamlessly bridge cell therapy research from early stages to commercialization, potentially enabling high-quality manufacturing and shortening R&D timelines.
Astellas has installed Yaskawa's dual-arm robot 'Maholo' since 2017, using it to advance drug discovery and manufacturing technology in cell therapy. In this partnership, Astellas will contribute its cell manufacturing technologies, clinical development, and regulatory expertise, while Yaskawa brings its clean environment robots and i³-Mechatronics solution concept, which integrates digital data with factory automation.
The platform may be offered to startups and academic institutions, potentially reducing investment burdens for investigational drug manufacturing under Japan's Pharmaceutical and Medical Device Act. The collaboration addresses key challenges such as low stability and reproducibility in cell therapy production, which often relies on craftsmanship, and the difficulty of transferring technology from basic research to GMP-compliant manufacturing.
Why it mattered
This partnership highlighted the growing role of industrial robotics in advanced therapy manufacturing, suggesting a future where automation could standardize cell therapy production, reduce costs, and accelerate the availability of new treatments. It also signaled Yaskawa's strategic expansion into medical applications, leveraging its expertise in mechatronics to address complex biomanufacturing challenges.
"The platform contemplated by both companies may then be provided to startups and academic institutions."
Source: Robotics & Automation News (roboticsandautomationnews.com) · Published 2024-08-05 · “Yaskawa partners with Astellas Pharma to build ‘innovative’ cell therapy platform combining robotics and pharmaceutical technologies”